Table 2 Univariate and multivariate Cox survival analyes of OS in PC patients.

From: Value of thyroid cancer history in the prognosis of pancreatic cancer: a SEER population-based study

Characteristics

Univariate analysis

Multivariate analysis

HR (95% CI)

P value

HR (95% CI)

P value

Age (Reference: < 68)

 68–79

1.637 (1.415–1.894)

 < 0.001

1.458 (1.253–1.697)

 < 0.001

  > 79

2.620 (2.222–3.089)

 < 0.001

1.917 (1.602–2.295)

 < 0.001

Sex (Reference: Female)

 Male

1.059 (0.924–1.215)

0.408

1.125 (0.977–1.295)

0.104

Race (Reference: Black)

 White

0.794 (0.655–0.963)

0.019

0.780 (0.639–0.954)

0.153

 Other

0.814 (0.645–1.028)

0.083

0.768 (0.605–0.975)

0.030

Tumor size (Reference: < 2.6)

 2.6–3.5

2.041 (1.700–2.450)

 < 0.001

1.213 (0.989–1.487)

0.063

  > 3.5

2.215 (1.874–2.617)

 < 0.001

1.372 (1.129–1.668)

0.001

 Grade (Reference: Well differentiated)

 Moderately differentiated

2.842 (2.103–3.842)

 < 0.001

1.958 (1.427–2.687)

 < 0.001

 Poorly differentiated

4.278 (3.132–5.844)

 < 0.001

2.472 (1.780–3.434)

 < 0.001

 Undifferentiated

3.671 (1.582–8.518)

0.002

1.969 (0.825–4.699)

0.127

 Unknown

6.081 (4.615–8.013)

 < 0.001

1.87 5(1.380–2.549)

 < 0.001

Radiotherapy (Reference: None/Unknown)

 Yes

0.797 (0.670–0.948)

0.010

0.991 (0.820–1.198)

0.924

Chemotherapy (Reference: None/Unknown)

 Yes

0.960 (0.843–1.093)

0.536

0.480 (0.429–0.582)

 < 0.001

Surgery (Reference: None/Unknown)

 Yes

0.256 (0.218–0.300)

 < 0.001

0.340 (0.268–0.431)

 < 0.001

AJCC T status (Reference: T1)

 T2

3.890 (2.811–5.385)

 < 0.001

1.394 (0.963–2.018)

0.079

 T3

3.845 (2.802–5.277)

 < 0.001

1.449 (1.000–2.100)

0.049

 T4

4.907 (3.523–6.835)

 < 0.001

1.225 (0.823–1.823)

0.318

 Unknown

8.497 (5.693–12.683)

 < 0.001

1.996 (1.282–3.106)

0.002

AJCC N status (Reference: N0)

 N1

1.124 (0.985–1.281)

0.082

1.192 (1.029–1.382)

0.019

 Unknown

2.834 (2.155–3.727)

 < 0.001

1.748 (1.315–2.323)

 < 0.001

AJCC M status (Reference: M0)

 M1

2.401 (2.110–2.732)

 < 0.001

1.826 (1.557–2.142)

 < 0.001

Primary site (Reference: Head of pancreas)

 Body of pancreas

0.911 (0.762–1.089)

0.307

0.844 (0.698–1.021)

0.081

 Tail of pancreas

0.744 (0.607–0.913)

0.005

0.789 (0.630–0.987)

0.038

 Pancreatic duct

1.518 (0.679–3.394)

0.310

1.270 (0.562–2.872)

0.566

 Other specified parts of pancreas

0.860 (0.576–1.284)

0.461

0.840 (0.559–1.262)

0.401

 Overlapping lesion of pancreas

1.081 (0.859–1.361)

0.506

1.007 (0.791–1.283)

0.953

 Pancreas, NOS

1.236 (0.927–1.648)

0.148

1.199 (0.887–1.620)

0.237

Histological subtype (Reference: Adenocarcinoma)

 Infiltrating duct carcinoma

0.510 (0.418–0.622)

 < 0.001

1.0245 (0.815–1.288)

0.836

 Neuroendocrine carcinoma

0.124 (0.086–0.180)

 < 0.001

0.153 (0.103–0.227)

 < 0.001

 Other

0.436 (0.351–0.543)

 < 0.001

0.552 (0.430–0.708)

 < 0.001

Prior thyroid cancer history (Reference: without)

 With

0.876 (0.702–1.093)

0.240

0.824 (0.652–1.041)

0.104

  1. OS overall survival, AJCC American Joint Commission on Cancer(7th), SEER the surveillance, epidemiology, and end results, HR hazard ratio, CI confidence interval.